TY - JOUR
T1 - Variant Interpretation for Dilated Cardiomyopathy
T2 - Refinement of the American College of Medical Genetics and Genomics/ClinGen Guidelines for the DCM Precision Medicine Study
AU - DCM Precision Medicine study
AU - DCM Consortium
AU - Morales, Ana
AU - Kinnamon, Daniel D.
AU - Jordan, Elizabeth
AU - Platt, Julia
AU - Vatta, Matteo
AU - Dorschner, Michael O.
AU - Starkey, Carl A.
AU - Mead, Jonathan O.
AU - Ai, Tomohiko
AU - Burke, Wylie
AU - Gastier-Foster, Julie
AU - Jarvik, Gail P.
AU - Rehm, Heidi L.
AU - Nickerson, Deborah A.
AU - Hershberger, Ray E.
AU - Gastier-Foster, Julie M.
AU - Bowen, Deborah J.
AU - Haas, Garrie
AU - Abraham, William T.
AU - Binkley, Philip F.
AU - Hasan, Ayesha
AU - Host, Jennifer
AU - Lampert, Brent
AU - Smith, Sakima
AU - Huggins, Gordon S.
AU - DeNofrio, David D.
AU - Kiernan, Michael
AU - Fishbein, Daniel
AU - Cheng, Richard
AU - Dardas, Todd
AU - Levy, Wayne
AU - Mahr, Claudius
AU - Masri, Sofia
AU - Stempien-Otero, April
AU - Gottlieb, Stephen S.
AU - Wheeler, Matthew
AU - Ashley, Euan
AU - Hofmeyer, Mark
AU - Wilson Tang, W. H.
AU - Starling, Randall
AU - Owens, Anjali
AU - Marguilies, Kenneth B.
AU - Cappola, Thomas
AU - Goldberg, Lee R.
AU - McLean, Rhondalyn
AU - Moore, Charles K.
AU - Long, Robert C.
AU - Carcamo, Javier Jimenez
AU - Trachtenberg, Barry
AU - Ewald, Gregory A.
N1 - Publisher Copyright:
© 2020 Lippincott Williams and Wilkins. All rights reserved.
PY - 2020/4/1
Y1 - 2020/4/1
N2 - Background: The hypothesis of the Dilated Cardiomyopathy Precision Medicine Study is that most dilated cardiomyopathy has a genetic basis. The study returns results to probands and, when indicated, to relatives. While both the American College of Medical Genetics and Genomics/Association for Molecular Pathology and ClinGen's MYH7-cardiomyopathy specifications provide relevant guidance for variant interpretation, further gene- and disease-specific considerations were required for dilated cardiomyopathy. To this end, we tailored the ClinGen MYH7-cardiomyopathy variant interpretation framework; the specifications implemented for the study are presented here. Methods: Modifications were created and approved by an external Variant Adjudication Oversight Committee. After a pilot using 81 probands, further adjustments were made, resulting in 27 criteria (9 modifications of the ClinGen MYH7 framework and reintroduction of 2 American College of Medical Genetics and Genomics/Association of Molecular Pathology criteria that were deemed not applicable by the ClinGen MYH7 working group). Results: These criteria were applied to 2059 variants in a test set of 97 probands. Variants were classified as benign (n=1702), likely benign (n=33), uncertain significance (n=71), likely pathogenic (likely pathogenic; n=12), and pathogenic (P; n=3). Only 2/15 likely pathogenic/P variants were identified in Non-Hispanic African ancestry probands. Conclusions: We tailored the ClinGen MYH7 criteria for our study. Our preliminary data show that 15/97 (15.5%) probands have likely pathogenic/P variants, most of which were identified in probands of Non-Hispanic European ancestry. We anticipate continued evolution of our approach, one that will be informed by new insights on variant interpretation and a greater understanding of the genetic architecture of dilated cardiomyopathy.
AB - Background: The hypothesis of the Dilated Cardiomyopathy Precision Medicine Study is that most dilated cardiomyopathy has a genetic basis. The study returns results to probands and, when indicated, to relatives. While both the American College of Medical Genetics and Genomics/Association for Molecular Pathology and ClinGen's MYH7-cardiomyopathy specifications provide relevant guidance for variant interpretation, further gene- and disease-specific considerations were required for dilated cardiomyopathy. To this end, we tailored the ClinGen MYH7-cardiomyopathy variant interpretation framework; the specifications implemented for the study are presented here. Methods: Modifications were created and approved by an external Variant Adjudication Oversight Committee. After a pilot using 81 probands, further adjustments were made, resulting in 27 criteria (9 modifications of the ClinGen MYH7 framework and reintroduction of 2 American College of Medical Genetics and Genomics/Association of Molecular Pathology criteria that were deemed not applicable by the ClinGen MYH7 working group). Results: These criteria were applied to 2059 variants in a test set of 97 probands. Variants were classified as benign (n=1702), likely benign (n=33), uncertain significance (n=71), likely pathogenic (likely pathogenic; n=12), and pathogenic (P; n=3). Only 2/15 likely pathogenic/P variants were identified in Non-Hispanic African ancestry probands. Conclusions: We tailored the ClinGen MYH7 criteria for our study. Our preliminary data show that 15/97 (15.5%) probands have likely pathogenic/P variants, most of which were identified in probands of Non-Hispanic European ancestry. We anticipate continued evolution of our approach, one that will be informed by new insights on variant interpretation and a greater understanding of the genetic architecture of dilated cardiomyopathy.
KW - cardiomyopathy, dilated
KW - genetic testing
KW - genetics
KW - genomics
KW - pathology, molecular
UR - http://www.scopus.com/inward/record.url?scp=85083913260&partnerID=8YFLogxK
U2 - 10.1161/CIRCGEN.119.002480
DO - 10.1161/CIRCGEN.119.002480
M3 - Article
C2 - 32160020
AN - SCOPUS:85083913260
SN - 2574-8300
VL - 13
SP - E002480
JO - Circulation: Genomic and Precision Medicine
JF - Circulation: Genomic and Precision Medicine
IS - 4
ER -